Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study in patients with psoriatic arthritis (PsA)/spondyloarthritis (SpA) reported in Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) registry , an independent, prospective, US observational cohort

Trial Profile

An observational study in patients with psoriatic arthritis (PsA)/spondyloarthritis (SpA) reported in Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) registry , an independent, prospective, US observational cohort

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary) ; Secukinumab (Primary) ; Adalimumab; Certolizumab pegol; Disease-modifying antirheumatics; Etanercept; Golimumab; Infliximab; Methotrexate
  • Indications Ankylosing spondylitis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2019 Results assessing the characteristics of patients who initiated secukinumab and other Biologics for the treatment of AS (n=106) presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2019 Results assessing the efficacy of of Apremilast and Methotrexate Monotherapy on patients with oligoarticular PsA (n=150) presented at the 20th Annual Congress of the European League Against Rheumatism
    • 18 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top